Our group focuses on engineering T cell states that are associated with immune rejection in cancers. We employ systems biology approaches to study molecular T cell states associated with deregulation or immune attack either at the steady state or following T cell therapy in the human and in mouse. Learning from such lessons, we engineer and reprogram tumor-specific T cells to achieve superior performance and tumor elimination,
- We use systems biology approaches to decipher the molecular T cell states associated with successful immune attack or immune failure in human and mouse tumors.
- In collaboration with Hi-TIDe’s Tumor microenvironment & biomarkers group and T cell discovery group, we capture tumor-infiltrating lymphocytes in human tumors in action, at the steady state or following adoptive T-cell therapy and other therapeutic perturbations, and interrogate them exhaustively to unveil the underlying T cell intrinsic signaling regulatory networks.
- Departing from prior knowledge and the above observations, we design novel synthetic T cell states, aspiring to overcome tumor immune resistance and T cell deregulation in order to defeat difficult cancers.
- We have developed the first generation GEEP-TTM (or Genetically Engineered for Enhanced Performance T) cells through orthogonal combinatorial engineering, i.e. introducing in therapeutic T cells desirable properties, such as stemness and cytotoxicity. We discovered that perturbations introduced in GEEP-T reprogrammed adoptively transferred T cells into new states conducive to tumor control without the need for host lymphodepletion .
- We characterize novel synthetic T cell states at the epigenetic, transcriptional, proteomic, and metabolomic level to infer new genetic perturbations with the potential to improve T cell antitumor efficacy.
- Using genetic screens along with mathematical modelling, we seek to understand and rationally manipulate CD8 T cell fate decisions. We seek to develop computational tools to reconstruct the transcriptional gene regulatory network underpinning CD8 T cell states, in order to further guide T cell engineering.
- We move our novel T cell technologies to the bedside, in collaboration with the other groups in the Hi-TIDe, the Center of Excellence for Cell Therapy, the Center of Experimental Therapeutics and the Service of immuno-oncology.
Advanced search is available through Serval
Publications can be managed by accessing Serval via MyUnil
Judah Folkman Award from the Alliance for Cancer Gene Therapy (2006); The Sir William Osler Award for Excellence in Patient Oriented Research from the University of Pennsylvania (2006); the Kimmel Scholar Award from the Sidney Kimmel Foundation (2008); the NIH Roadmap, Director’s Transformative Award (2010); the Claudia Cohen Research Award for Ovarian Cancer (2012); the Advanced Grant award from the European Research Council (2013); and the Helga Salvesen Award for Best Translational Research, European Society of Gynaecologic Oncology (2019).
Pr George Coukos is Head of the Department of oncology UNIL CHUV, Director of the Lausanne Branch of the Ludwig Institute for Cancer Research, and Head of the Service of immuno-oncology at the Lausanne University Hospital. He is equally co-director of the Swiss Cancer Center Léman, which he co-founded in 2016 with Pr Douglas Hanahan (EPFL) and Pr Pierre-Yves Dietrich (HUG and UNIGE).
He has a distinguished career with over 20 years' experience as both clinician and surgeon as well as leading investigator in the field of tumor immunology and immunotherapy. During his tenure at the University of Pennsylvania, Pr Coukos founded and directed the Ovarian Cancer Research Center, dedicated to translational research and development of innovative therapies for ovarian cancer, and served as Associate Director of the Division of Gynecologic Oncology.
His research work at Penn focused on elucidating fundamental mechanisms in the tumor microenvironment that determine the fate of antitumor immunity, especially the deregulation of tumor-infiltrating lymphocytes (TILs), with a translational focus largely concentrated on ovarian cancer. His laboratory discovered the presence of spontaneous antitumor immune response in ovarian cancer, disrupting the previous dogma that only few tumor types (e.g. melanoma or renal cell cancer) are immunogenic. It then characterized mechanisms driving TIL dysfunction at the tumor microenvironment. Among them, the role of tolerogenic myeloid cells, T regulatory cells, and notably tumor vasculature immune checkpoints. George Coukos was the first to propose the novel notion of the tumor endothelial barrier, i.e. that the vasculature actively controls T cell homing in tumors. Different molecular mechanisms were identified, offering novel therapeutic targets for cancer immunotherapy. Several clinical trials are presently ongoing, testing the combination of anti-angiogenesis drugs with immunotherapy by Coukos and others.
While at Penn, George Coukos played an active role translating novel lessons from the laboratory to the clinic through early phase clinical trials. Notably, he developed an autologous dendritic cell-based vaccine as well as adoptive T cell therapy with vaccine-primed autologous T cells in ovarian cancer. Currently, he is leading development and testing adoptive therapy with neoantigen-enriched tumor infiltrating lymphocytes in solid tumors.
In Lausanne, George Coukos established and directs the Hi-TIDe and the Center for Excellence in Cell Therapy, which are focused on developing and testing curative T cell therapies for solid tumors.
Learn more about Pr George Coukos: